Leukemia stem cells (LSCs) pose a significant challenge in treating acute myeloid leukemia (AML) due to their resistance to ...

A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Transplant or no transplant for TP53 ...

In a heartfelt testament to the power of family and community, Amanda Busch, an oncology pharmacist and mother of two, shared ...

New York, USA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight DelveInsight’s Allogeneic ...

BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, ...

The following is a summary of “Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

Comprehensive analysis of hematopoietic alternations with age shows a discrepancy of age-associated changes between peripheral blood and bone marrow (C) Percentage chimerism at 16 weeks after ...

A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic ...

The other patient was diagnosed with acute myeloid leukemia (AML) at 57 months. Six patients were subsequently treated with ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today ...

with a particular focus on describing the mechanism of action in the leukemia stem cell population. NMT2 expression was identified as a marker for Acute Myeloid Leukemia (AML) patient survival, and ...